According to the announcement, Antares will receive a $5 million initial payment and up to $15 million in additional milestone payments. Antares Pharma will record all product revenue associated with future dermatology prescriptions and pay LEO Pharma a percentage of Otrexup net sales generated in dermatology. LEO Pharma will be responsible for promotion and marketing activities in dermatology.